There were no differences in the incidence of grade II-IV acute GVHD (32% [95% CI: 18–48%] vs. 19% [95% CI: 8–34%], P = 0.24, Fig. S3b) or in the neutrophil recovery of >0.5 × 109/L (89% [95% CI: 72–96%] vs. 92% [95% CI: 74–98%] at 30 days after HCT, P = 0.89, Fig. S3c) between the groups with and without CD34+mono. The gene discussed is CD34; the disease is acute graft versus host disease.